The in vitro antitumor activity of novel combretastatin-like 1,5- and 1,2-diaryl-1H-imidazoles was evaluated against the NCI 60 human tumor cell lines panel. Compounds 2d and 2g proved to be more cytotoxic than CA-4 in tests involving their evaluation over a 10(-4)-10(-8) range. Docking experiments showed a good correlation between the MG_MID Log GI(50) values of all these compounds and their calculated interaction energies with the colchicine binding site of alpha beta-tubulin. (c) 2006 Elsevier Ltd. All rights reserved
There is a clear need for anti-cancer therapies that have effective cytotoxic efficiency and margin...
Cancer is the second most common cause of death in the USA. Among the known classes of anticancer ag...
Tubulin, the major structural component of microtubules, is a target for the development of antican...
Combretastatin (CA-4) and its analogues are undergoing several clinical trials for treating differen...
Combretastatin (CA-4) and its analogues are undergoing several clinical trials for treating differen...
A series of novel 3-alkyl-1,5-diaryl-1H-pyrazoles were synthesized as combretastatin A-4 (CA-4) anal...
ABSTRACT: A series of novel pyridine-bridged analogues of combretastatin-A4 (CA-4) were designed and...
A series of novel pyridine-bridged analogues of combretastatin-A4 (CA-4) were designed and synthesiz...
A novel series of tubulin polymerization inhibitors, based on the 1-(3’,4’,5’-trimethoxyphenyl)-2-ar...
Tubulin, the major structural component of microtubules, is a target for the development of anticanc...
<div><p>A series of novel 3-alkyl-1,5-diaryl-1<i>H</i>-pyrazoles were synthesized as combretastatin ...
A novel class of combretastatins, modified at A-ring or both A- and B-rings, mainly by replacement w...
A series of chiral β-lactam bridged analogues (3-substituted 1,4-diaryl-2-azetidinones) of combretas...
Combretastatin A-4 (CA-4) in phosphate and serine pro-drug forms is under phase II clinical trials. ...
Specific targeting of the tumoral vasculature by vascular-disrupting agents (VDA), of which combreta...
There is a clear need for anti-cancer therapies that have effective cytotoxic efficiency and margin...
Cancer is the second most common cause of death in the USA. Among the known classes of anticancer ag...
Tubulin, the major structural component of microtubules, is a target for the development of antican...
Combretastatin (CA-4) and its analogues are undergoing several clinical trials for treating differen...
Combretastatin (CA-4) and its analogues are undergoing several clinical trials for treating differen...
A series of novel 3-alkyl-1,5-diaryl-1H-pyrazoles were synthesized as combretastatin A-4 (CA-4) anal...
ABSTRACT: A series of novel pyridine-bridged analogues of combretastatin-A4 (CA-4) were designed and...
A series of novel pyridine-bridged analogues of combretastatin-A4 (CA-4) were designed and synthesiz...
A novel series of tubulin polymerization inhibitors, based on the 1-(3’,4’,5’-trimethoxyphenyl)-2-ar...
Tubulin, the major structural component of microtubules, is a target for the development of anticanc...
<div><p>A series of novel 3-alkyl-1,5-diaryl-1<i>H</i>-pyrazoles were synthesized as combretastatin ...
A novel class of combretastatins, modified at A-ring or both A- and B-rings, mainly by replacement w...
A series of chiral β-lactam bridged analogues (3-substituted 1,4-diaryl-2-azetidinones) of combretas...
Combretastatin A-4 (CA-4) in phosphate and serine pro-drug forms is under phase II clinical trials. ...
Specific targeting of the tumoral vasculature by vascular-disrupting agents (VDA), of which combreta...
There is a clear need for anti-cancer therapies that have effective cytotoxic efficiency and margin...
Cancer is the second most common cause of death in the USA. Among the known classes of anticancer ag...
Tubulin, the major structural component of microtubules, is a target for the development of antican...